Sydnexis is decreasing myopic progression in children.

Formulation Matters!
Our patented formulation is designed for comfort and efficacy.
See How

Sydnexis is decreasing myopic progression in children.

See How

A novel, stable, & comfortable topical eyedrop used once daily at bedtime.

See How
The STAR Study Logo

Treating Myopia with the STAR Study

A Phase 3 study to treat the progression of myopia in children.
Learn More

Are you a patient?

Learn more about Myopia & how to treat it.
Click Here

Latest News

Sydnexis Welcomes Nick Ruth as Chief Commercial Officer
Sydnexis is excited to announce the appointment of Nick Ruth, MBA, as its Chief Commercial Officer.
Read More
August 30, 2023
Sydnexis Featured in Review of Myopia Management
To learn more directly from the founders of Sydnexis about what makes their formula unique and how it will benefit juvenile-onset myopic children, Review of Myopia Management caught up with Gregory Ostrow, MD, and Patrick Johnson, PhD, and conducted the following interview.
Read More
August 15, 2023
Previous News